Incontinence-associated dermatitis Skin and Connective Tissue Diseases Unspecified contact dermatitis due to other agents
Conditions
Interventions
The project is organised into four elements. Work Package 1 relates to the ethics application. Initial work with human volunteers (Work Package 2) will establish the actual thickness of RD1433 require
Vaseline™) within Work Package 4. This experimental approach will enable an efficacy assessment for both prevention and treatment strategies. The corresponding data would be collated into a final rep
Sponsors
Bracco Healthcare (USA)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age >17 years 2. Generally healthy 3. Willing to attend up to three, five day sessions
Exclusion criteria
Exclusion criteria: 1. Dark-skinned volunteers. (This is because darker skin may affect some of the measurements we intend to make, as our instruments rely on being able to detect changes in skin colour and blood flow. The presence of melanin (the substance responsible for darkening the skin) reduces the sensitivity of our equipment. This will not affect the outcome of our study ? if the treatment is successful, it will work on all skin types.) 2. Pre-existing skin disease such as eczema, dermatitis or skin allergy 3. Concurrent use of aspirin, paracetamol or any other anti-inflammatory drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Significant reduction in vascular perfusion (Laser Doppler imaging; arbitrary perfusion units) 2. Significant reduction in erythema (skin reflectance spectroscopy; CIELAB ?a*? parameter) 3. Significant reduction in transepidermal water loss (evaporimetry; mg/cm2/h) 4. Significant reduction in skin surface temperature (infrared imaging; °C) | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
United Kingdom
Outcome results
None listed